A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Public ClinicalTrials.gov record NCT06824467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
Study identification
- NCT ID
- NCT06824467
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 770 participants
Conditions and interventions
Interventions
- Acetaminophen (or equivalent) Drug
- Bevacizumab Biological
- Dexamethasone (or equivalent) Drug
- H1 receptor antagonist Drug
- H2 receptor antagonist Drug
- Sacituzumab tirumotecan Biological
- Steroid mouthwash (dexamethasone or equivalent) Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2025
- Primary completion
- Apr 26, 2029
- Completion
- Nov 8, 2032
- Last update posted
- May 7, 2026
2025 – 2032
United States locations
- U.S. sites
- 30
- U.S. states
- 21
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham ( Site 0006) | Birmingham | Alabama | 35249 | Recruiting |
| Alaska Women's Cancer Care ( Site 0096) | Anchorage | Alaska | 99508 | Recruiting |
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) | New Haven | Connecticut | 06510 | Recruiting |
| Mount Sinai Cancer Center ( Site 0078) | Miami Beach | Florida | 33140 | Recruiting |
| Sarasota Memorial Hospital ( Site 0075) | Sarasota | Florida | 34239 | Recruiting |
| Florida Cancer Specialists East ( Site 7000) | West Palm Beach | Florida | 33401 | Recruiting |
| Winship Cancer Institute of Emory University ( Site 0086) | Atlanta | Georgia | 30322 | Recruiting |
| Augusta University - Georgia Cancer Center ( Site 0066) | Augusta | Georgia | 30912 | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0003) | Fort Wayne | Indiana | 46845 | Recruiting |
| Women's Cancer Care ( Site 0067) | Covington | Louisiana | 70433 | Recruiting |
| Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008) | Scarborough | Maine | 04074 | Recruiting |
| St. Dominic's Hospital ( Site 0064) | Jackson | Mississippi | 39216 | Active, not recruiting |
| Nebraska Methodist Hospital ( Site 0053) | Omaha | Nebraska | 68114 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081) | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0071) | New Brunswick | New Jersey | 08901 | Recruiting |
| University of New Mexico Comprehensive Cancer Center ( Site 0055) | Albuquerque | New Mexico | 87131 | Recruiting |
| NYU Langone Hospital - Long Island ( Site 0015) | Mineola | New York | 11501 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center ( Site 0076) | New York | New York | 10016 | Recruiting |
| FirstHealth Cancer Center ( Site 0079) | Pinehurst | North Carolina | 28374 | Recruiting |
| University of Cincinnati Medical Center ( Site 0090) | Cincinnati | Ohio | 45219 | Recruiting |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054) | Columbus | Ohio | 43210 | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056) | Tulsa | Oklahoma | 74146 | Recruiting |
| Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010) | Eugene | Oregon | 97401 | Recruiting |
| Women & Infants Hospital ( Site 0050) | Providence | Rhode Island | 02905 | Recruiting |
| Henry-Joyce Cancer Clinic ( Site 0060) | Nashville | Tennessee | 37232 | Recruiting |
| Texas Oncology - Central/South Texas ( Site 8009) | Austin | Texas | 78758 | Recruiting |
| Texas Oncology - DFW ( Site 8001) | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology - San Antonio ( Site 8005) | San Antonio | Texas | 78240 | Recruiting |
| Texas Oncology - Gulf Coast ( Site 8003) | Webster | Texas | 77598 | Recruiting |
| Virginia Cancer Specialists (VCS) ( Site 8011) | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06824467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06824467 live on ClinicalTrials.gov.